Fig. 6: Comparing SomaScan/Olink effect-estimates from significant (p < 0.05) Alzheimer’s Disease (AD) Mendelian Randomization (MR) results, from inverse-variance weighted MR analyses (two-sided tests).
From: Cross-ancestry comparison of aptamer and antibody protein measures
The genetic instruments tests for these MR tests include A all cis-pQTL for each platform (Referred to as Model 1 (p value p1), B all cis-pQTL except for platform-discordant protein-altering variants (PAV) (Referred to as Model 2—p value p2), C all cis-pQTL except for platform-discordant and platform-specific PAVs for each platform (Referred to as Model 3—p value p3). D Tabular summary of significant results from MR models, including SomaScan pQTL instruments only or Olink pQTL instruments only. The bottom row summarizes the results for the subset of genes that were tested in both the SomaScan and Olink MR models. In all models, a nominal p value threshold of 0.05 was used to define significance. Source data is available in Supplementary Data 26 and 27.
